208 related articles for article (PubMed ID: 31233398)
1. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
4. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
Karakas C; Tyburski H; Turner BM; Wang X; Schiffhauer LM; Katerji H; Hicks DG; Zhang H
Am J Clin Pathol; 2023 May; 159(5):484-491. PubMed ID: 36856777
[TBL] [Abstract][Full Text] [Related]
5. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
[TBL] [Abstract][Full Text] [Related]
6. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH).
Mayr D; Heim S; Werhan C; Zeindl-Eberhart E; Kirchner T
Virchows Arch; 2009 Mar; 454(3):241-8. PubMed ID: 19169706
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
[TBL] [Abstract][Full Text] [Related]
9. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
[TBL] [Abstract][Full Text] [Related]
10. Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone.
Layfield LJ; Frazier S; Esebua M; Schmidt RL
Pathol Res Pract; 2016 Mar; 212(3):190-5. PubMed ID: 26839158
[TBL] [Abstract][Full Text] [Related]
11. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
15. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver
Miladinović M; Vučković L; Klisic A
Open Med (Wars); 2021; 16(1):1503-1512. PubMed ID: 34708154
[TBL] [Abstract][Full Text] [Related]
17. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit.
Jørgensen JT; Møller S; Rasmussen BB; Winther H; Schønau A; Knoop A
Am J Clin Pathol; 2011 Jul; 136(1):145-51. PubMed ID: 21685042
[TBL] [Abstract][Full Text] [Related]
18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Dual-ISH (DISH) With Fluorescence In Situ Hybridization (FISH) and Correlation With Immunohistochemical Findings for HER2/Neu Status in Breast Carcinoma.
Layfield LJ; Wallander ML; Tripp SR; Redpath S; Banks PM
Appl Immunohistochem Mol Morphol; 2017 Apr; 25(4):231-236. PubMed ID: 26766122
[TBL] [Abstract][Full Text] [Related]
20. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
